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Introduction
G protein coupled receptors (GPCRs), which play an important 
role in several physiological and pathophysiological processes, and 
thus, are targets of important drugs, consist of seven transmembrane 
domains, which are connected by intra- and extracellular loops [1-
3]. Antagonists stabilize the inactive conformation of a GPCR while 
partial agonists or full agonists induce a conformational change of the 
GPCR from the inactive state into the active state [4]. GPCRs, activated 
by an agonist, interact in the intracellular part with a heterotrimeric G 
protein, consisting of a α-, β- and γ-subunit, and the signal cascade is 
induced [5].
Weiland et al. (1979) were the first, who observed a thermodynamic 
discrimination of antagonists and agonists at the β-adrenergic receptor 
[6]. Subsequently, a large number of studies at different GPCRs were 
performed in order to determine thermodynamics of ligand binding: 
For example, addressing the β2 adrenergic receptor [6-9], the serotonin 
5-HT1A-receptor [10], the dopamine D2 receptor [11,12], the histamine 
H1 receptor [13] and the histamine H3 receptor [14]. These receptors 
belong to the aminergic GPCRs of the GPCR family A [3]. Additionally, 
distinct studies at other GPCRs, for example at the adenosine A1, A2A, 
A2B and A3 receptors [15-19], the cholecystokinin CCK2 receptor [20] 
or cannabinoid CB1 and CB2 receptors [21] are performed. More 
references may be found in previous reviews [22-24] and a summary of 
most important data is shown in Table 1.
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Ligand-Receptor Binding in the Framework of Thermo-
dynamics 
To distinguish between the properties of various ligand types and 
its receptors on the base of thermodynamic properties a correlation 
of the efficacy as a function of pKi values is to be done.  As it is not 
possible up to now to predict both quantities completely with the 
help of theoretical based models, experimentally determined values of 
the mentioned variables may be used in order to establish rules for a 
thermodynamic based discrimination of antagonists, partial agonists 
and full agonists with respect to a given receptor. Having a look on 
the efficacy and the pKi values of ligands at a GPCR, it is impossible to 
decide on antagonism or agonism using the pKi values or equivalently 
the Gibbs reference energy for the ligand-receptor binding (ΔGο). 
Taking into account the basic relation [13,24] connecting the reference 
enthalpy for the ligand-receptor binding (ΔHο) and the reference 
entropy for the ligand-receptor binding (ΔSο) with the quantity ΔGo, T 
represents the absolute temperature,
ΔGo=ΔHo–T•ΔSo
an attempt may be made to distinguish between the various types of 
ligands on the base of the reference enthalpy and reference entropy. The 
experimental determination of ΔHo and ΔSo however is not a simple 
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task because it is to be assured that the measurement exactly reflects 
the properties of the association process and may not be influenced 
by secondary effects. In this context, the assay conditions may play an 
important role, as discussed in more detail in the next paragraph.
Dependence of Thermodynamic Parameters from Assay 
Conditions
The thermodynamic analysis of ligand binding to the guinea-pig 
histamine H3 receptor was performed at two different assay conditions 
[14]. Within the first series HEPES-NaOH buffer (buffer A) was used, 
whereas in a second series HEPES-NaOH buffer, containing 300 mM 
CaCl2 (buffer ACa) was used. The binding of agonists in buffer A to 
gpH3R were entropy driven, whereas the binding of antagonists was 
enthalpy- and entropy-driven. In contrast, the binding of both, agonists 
(except immepip) and antagonists, was enthalpy- and entropy-driven 
in buffer ACa. However, for the agonists the entropic term was much 
more negative, compared to the enthalpic term. Thus, thermodynamic 
parameters, concerning the ligand binding process, determined at 
different assay conditions, have to be handled separately.
Thermodynamics of Ligand Binding to GPCRs – Terms, 
Which Have to be Taken into Account
In case that a ligand binds to a GPCR several terms have to be 
taken into account. First of all, the solvation shell of the ligand has to be 
destroyed, thus, enthalpy and entropy of ligand desolvation has to be 
taken into account. However, molecular dynamic simulations suggest 
that water molecules in the binding pocket may mediate the interaction 
between ligand and receptor [25,26]. Furthermore, the number of 
water molecules present in the binding pocket may differ between 
different ligands and different GPCRs. Here, the polar/non-polar 
moieties of the ligand may play a very important role, independent, if 
a ligand acts as an antagonist or agonist. The second important term 
arises by the interaction of the ligand with the binding pocket. Third, 
several studies suggest ligand-dependent conformations of GPCRs. Of 
course, different receptor conformations may exhibit differences with 
regard to enthalpic and entropic terms. Thus, it may be suggested that 
especially antagonist-stabilized (inactive conformation) and agonist-
stabilized (active conformation) receptor conformations have large 
differences in enthalpy and entropy. 
Species Differences in Thermodynamics of Ligand 
Binding
For the histamine H1 receptor, an extensive study, addressing the 
thermodynamics of ligand binding was performed at the human H1R 
and guinea-pig H1R (Figure 1) [13]. In general, the data reveals species 
differences, in dependence of the ligand, for the thermodynamic 
properties ΔHo(p,To), -TΔSo(p,To) and ΔGo(p,To). For the tricyclic 
compounds amitryptiline (Figure 1, cpd 5), mianserin (Figure 1, cpd 6) 
and clozapine (Figure 1, cpd 7) no significant species differences were 
found in affinity at a temperature of 293.15 K. But significant species 
differences were determined with regard to ΔHo(p,To) and  -TΔSo(p,To). 
Thus, species differences often will be revealed not until considering 
enthalpy and entropy. Furthermore, for an efficient development 
of new, highly affine drugs, it will be very useful to include not only 
pKi-values, which correlate with ΔGo(p,To) into adequate structure-
GPCR no. of analyzed ligands range for ΔHo(p,To) [kJ/mol] range for -TΔS
o(p,To) [kJ/mol] ref.
βRs
agonists 13 -143 to -17 -8 to 93
[23]
antagonists 15 -21 to 16 -53 to -16
hH1R
agonists 14 -37.6 to 25.6 -59.6 to 5.8
[13]
antagonists 10 -1.5 to 80.2 -120.7 to -42.4
gpH1R
agonists 16 -24.1 to 41.8 -77.4 to -6.8
[13]
antagonists 8 1.0 to 98.8 -145.9 to -49.2
gpH3R
agonists 7 6.4 to 44.5 (buffer A),-9.2 to 15.1 (buffer ACa)
-92.0 to -58.3 (buffer A),
-60.7 to -38.1 (buffer ACa) [14]
antagonists 3 -34.1 to -22.9 (buffer A),-40.7 to -10.5 (buffer ACa)
-35.1 to -16.9 (buffer A),
-43.8 to -10.3 (buffer ACa)
D2R
agonists 11 -224 to 90 -136 to 176
[23]
antagonists 22 -89 to 59 -105 to 107
sheep D2R
agonists 1 90.0 (high affinity); 54.4 (low affinity)
-136.0 (high affinity);
 -91.1 (low affinity) [12]
antagonists 3 14.6 to 58.6 -107.3 to -72.4
r5-HT1AR
agonists 8 -65 to 58 -109 to 20
[10]
antagonists 7 15 to 80 -109 to -47
hCB1R
agonists 5 17 to 59 -108 to -64
[21]
antagonists 3 -52 to -26 -11 to 4
hCB2R
agonists 5 27 to 48 -89 to -70
[21]
antagonists 3 -19 to -17 -22 to -13
A1R
agonists 6 19 to 46 -106 to -61
[18]
antagonists 6 -37 to -20 -18 to 7
A2AR
agonists 6 7 to 50 -83 to -53
[18] 
antagonists 6 -45 to -7 -28 to -4
A2BR
agonists 6 7 to 23 -65 to -37
[18]
antagonists 6 -40 to -20 -27 to -3
A3R
agonists 6 21 to 67 -122 to -67
[18]
antagonists 5 -52 to -9 -24 to -5
Table 1: Summary of thermodynamics studies, addressing GPCRs. This table gives a summary of most important data, available in literature. However, within this 
table, different assay conditions or species for data regarding one distinct receptor are not taken into account in all cases. For detailed information, the reader is referred 
to the mentioned references.
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activity-studies, but also enthalpic and entropic terms of the ligand 
binding process [27].
Influence of the Target onto Thermodynamic Param-
eters for Ligand Binding
Mianserin for example was studied thermodynamically at the 
human and guinea-pig histamine H1 receptor [13] and at the rat 
serotonin 5-HT1A receptor [10]. At the hH1R, the enthalpy for ligand 
binding is 32.6 kJ/mol, whereas it is significantly higher at gpH1R with 
72.2 kJ/mol. The entropic term (-TΔSo(p,To)) for binding of mianserin 
to hH1R is -82.0 kJ/mol and to gpH1R -121.7 kJ/mol. But in contrast the 
corresponding terms of the Gibbs energy of ligand binding given by 
-49.4 kJ/mol at hH1R and -49.5 kJ/mol at gpH1R are nearly equal. The 
enthalpic term for binding of mianserin to the rat 5-HT1AR is 15 kJ/
mol and the entropic term is -46.5 kJ/mol. The Gibbs energy of binding 
of mianserin to the rat 5-HT1AR is -31.5 kJ/mol. The thermodynamic 
parameters of one ligand at different targets – not only different species, 
but especially different GPCRs – are very interesting, because the 
contribution of desolvation of the ligands should be equal in this case. 
Thus, only the GPCR and GPCR-ligand-complex has influence onto 
the observed thermodynamic parameters. Furthermore, mianserin 
acts as an antagonist at hH1R and gpH1R, as well as at the rat 5-HT1AR. 
Thus, the mentioned receptors are suggested to be stabilized in its 
inactive conformation and no conformational change due to receptor 
activation will take place. A comparison of these data show in general, 
that the binding of mianserin to hH1R, gpH1R and rat 5-HT1AR is 
strongly entropy driven, indicating an increase of flexibility during the 
association process. On the other hand the enthalpic term is positive 
at the three GPCRs reflecting the fact that the ligand receptor complex 
is not favoured energetically. Nevertheless the corresponding Gibbs 
energy exhibits negative values in all three cases, in which mianserin 
shows equal affinity to hH1R and gpH1R whereas the affinity to rat 
5-HT1AR is significantly smaller (Figure 2). 
Chiral Compounds and Thermodynamics of Ligand 
Binding
At the histamine H1 receptor [13], and the adrenergic β2 receptor 
(hβ2R), the enthalpy and entropy of ligand binding was studied for 
chiral compounds, including both enantiomers [8,9]. As mentioned 
above, the enthalpy and entropy of desolvation of the ligand is 
suggested to have an influence onto enthalpy and entropy of ligand 
binding to a target. For enantiomers, the enthalpic and entropic terms 
of desolvation are identical. Thus, enantiomers are very interesting 
compounds for studying thermodynamics, since the observed enthalpy 
and entropy of ligand binding reflects only the GPCR or GPCR-ligand 
complex, but the desolvation of the ligand does not account for direct 
comparison of the thermodynamic properties for enantiomers. At the 
hH1R and gpH1R, chiral phenylhistamines and phenoprodifens were 
studied [13]. The chiral phenylhistamines act as partial agonists at hH1R 
and gpH1R. For the (R)-phenylhistamine (exact: (R)-1-(2-phenyl-1H-
imidazol-4-yl)propan-2-amine), a positive enthalpy of binding was 
found at hH1R and gpH1R and the entropic term ‐TΔS° is in negative 
stage. In contrast, for the (S)-phenylhistamin (exact: (S)-1-(2-phenyl-
1H-imidazol-4-yl)propan-2-amine), a negative enthalpy of binding 
and entropy of binding (-TΔS) was observed at hH1R and gpH1R. Thus, 
the binding of (R)-phenylhistamine is entropy-driven, whereas the 
binding of the (S)-phenylhistamine is entropy- and slightly enthalpy-
driven. The efficacies between the (R)- and (S)-phenylhistamine are not 
significantly different at hH1R (Emax, (R): 0.21, (S): 0.23) or gpH1R (Emax, 
(R): 0.51, (S): 0.78) [28]. Thus, it may be concluded, that the differences 
in enthalpy and entropy between the (R)- and (S)-phenylhistamine can 
be related with the different binding conformation of both ligands due 
to the difference induced by the center of chirality. This may lead to 
different interactions between the ligand and the receptor. Additionally, 
a different number of water molecules may be located in the binding 
pocket and act as mediator of interaction between the ligand and 
the receptor. The interpretation of the data with regard to the chiral 
phenoprodifens is more complicated, since the phenoprodifens are 
suggested to bind in two different orientations into the binding pocket 
of the histamine H1 receptor [13,28]. The (R)- and (S)-phenoprodifen 
(exact: (R)-N-(2-(2-(3,3-diphenylpropyl)-1H-imidazol-4-yl)ethyl-1-
(2-phenyl-1H-imidazol-4-yl)propan-2-amine and (S)-N-(2-(2-(3,3-
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Figure 1: Thermodynamic Parameters for Binding of Antagonists and 
(Partial) Agonists to hH1R and gpH1R [13]. Antagonists: 1, mepyramine; 
2, diphenhydramine; 3, fexofenadine; 4, terfenadine; 5, amitriptyline; 6, 
mianserin; 7, clozapine; 8, chlorpromazine. (Partial) agonists: 9, histamine; 
10-13, phenylhistamines; 14-19, histaprodifens; 20, suprahistaprodifen; 21-
23, phenoprodifens; 24, dimeric histaprodifen.
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Figure 2: Gibbs Energy of Activation for Association of Ligands to 
hH1R and gpH1R. The data are calculated using the Eyring equation and 
the rate constants for association [34].
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diphenylpropyl)-1H-imidazol-4-yl)ethyl-1-(2-phenyl-1H-imidazol-
4-yl)propan-2-amine)  act as antagonist at hH1R (Emax, (R): 0.05, (S): 
0.04) and as partial agonist at gpH1R (Emax, (R): 0.60, (S): 0.23) [28]. 
For hH1R or gpH1R, no large differences for the enthalpic and entropic 
term of ligand binding were observed between the (R)- and (S)-
phenoprodifen [13]. However, within this study, it was the first time, 
that a temperature-dependent QSAR-study was used to predict the 
enthalpic- and entropic-term for both orientations of the (R)- and (S)-
phenoprodifen. These data reveal large species differences in enthalpic 
and entropic terms for orientation 1, but rather no species differences 
for orientation 2 of the chiral phenoprodifen derivatives [13]. 
Furthermore, this prediction of the thermodynamic data suggests, that 
the differences in enthalpic and entropic terms may be related with the 
preferred binding mode of the chiral phenoprodifen derivatives [13]. 
Similar studies were performed for four fenoterol stereoisomers at the 
adrenergic β2 receptor [8]. Since the studied fenoterol stereoisomers 
include two enantomeric pairs: (S,S’)–(R,R’) and (S,R’)–(R,S’), the 
resulting data of the corresponding enantiomers can be directly related 
the β2R-fenoterol-complex and desolvation terms have no influence. 
The observed differences in enthalpy and entropy of fenoterol binding 
to the β2R may represent differences in binding mode of the ligand, 
as well as differences in number of water molecules in the binding 
pocket. Furthermore, since the fenoterol derivatives act as full agonists 
at the β2R, different conformations of the β2R have to be taken into 
account. The authors relate the chirality of the carbon atom containing 
the β-OH-moiety as a key factor, with regard to enthalpy- or entropy-
driven binding process of a fenoterol stereoisomer [8]. R-configuration 
leads to an entropy-driven binding process, whereas for S-configuration 
an enthalpy-driven binding process was observed. 
Contributions of Molecular Modelling Studies
Several molecular modelling methods allow to predict 
thermodynamic properties. Unfortunately, in most cases the 
prediction is restricted to enthalpic terms. However, some methods, 
like the thermodynamic integration method [29,30] allow calculation 
of the Gibbs energy of solvation [31]. The central process responsible 
for discrimination between antagonists and (partial) agonists is the 
receptor activation defined by the Gibbs energy of activation reflecting 
the structural change of the empty receptor and the state where the 
agonist is removed from the activated receptor without allowing 
to relax its structure. As this process is not subject to experimental 
methods, molecular modelling studies may be used to investigate 
this single process. Unfortunately the calculations used by modelling 
techniques are based entirely on energetic terms and therefore lacks 
entropic contributions in describing states or processes, so the changes 
in Gibbs energy during a process may not calculated directly. To get 
such a quantity, it is necessary to make use of specific methods like the 
thermodynamic integration method [29,30]. The equation determining 
the reference Gibbs energy of receptor activation ΔGo(R→R*) from a 
thermodynamic point of view reads as ΔGo(R→R*)=Go(R*)–Go(R), 
where Go(R*) represents the reference Gibbs energy of the active, 
unrelaxed receptor without ligand and Go(R) represents the reference 
Gibbs energy of the inactive receptor without ligand. The derivation of 
this relation and the corresponding integration method itself, which 
may be extended to the estimation of all the effects already mentioned, 
is given in the literature [26,29,30].
From Binding Kinetics to Thermodynamic Quantities
Considering a simple model for the ligand-receptor association 
L+R⇌LR determining the rate constants for association (k1) 
and dissociation (k-1) provides an alternative method to obtain 
thermodynamic quantities. In this context, the constant for ligand-
receptor binding K is given by k1/k-1. Furthermore, binding kinetics 
should be used to ensure the state of chemical equilibrium, which is 
necessary for a direct determination of thermodynamic quantities as 
discussed in the foregoing paragraphs. The Eyring equation relates the 
rate constants to the Gibbs energy of activation ΔG≠ for the chemical 
process of association and dissociation [32,33]. 
In case of hH1R and gpH1R, an antagonist (mepyramine), a partial 
agonist (phenoprodifen) and a full agonist (histamine) were analyzed 
concerning the rate constants of association and dissociation at 293.15 
K [34]. Within the series antagonist → partial agonist → full agonist the 
Gibbs energy of activation for the association process increases at hH1R 
and gpH1R. Thus, in addition to a “thermodynamic discrimination” a 
“kinetic discrimination” of antagonist, partial agonist and full agonists 
may be considered. Antagonists stabilize the inactive conformation of 
a GPCR, without inducing a conformational change of the GPCR. In 
contrast, partial or full agonists induce a conformational change [4]. 
Thus, a larger Gibss energy of activation for the binding of agonists, 
compared to antagonists sounds reasonable. Moreover, a temperature 
dependent measurement of rate constants followed by the calculation 
of the Gibbs energy of activation, leads to the enthalpy and entropy 
of activation by the same machinery as in pure thermodynamics. For 
example, at the guinea-pig histamine H3 receptor, the rate constants 
for association and dissociation of [3H]clobenpropit was determined 
in dependence of temperature [14]. Based on these rate constants, the 
Gibbs energy, enthalpy and entropy of activation for the association 
process can be calculated (Figure 3, Table 2). Taking into account the 
experimental errors based on the data in literature [14], the entropy 
term of activation is zero. Thus, the reaction rates of association 
and dissociation are only determined by enthalpy (Table 2). For 
the association process the enthalpy is about 86 kJ/mol and for the 
dissociation process about 105 kJ/mol (Table 2). But to establish the 
kinetic discrimination as a useful method to distinguish between the 
various types of ligands an intensive analysis of more data sets has to 
be done.
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Figure 3: Gibbs Energy of Activation for the Association or Dissociation 
and ΔGo of [3H]Clobenprobit to gpH3R as Function of Temperature. The 
data are calculated using the Eyring equation and the corresponding rate 
constants for association or dissociation and pKi values given in literature 
[14].
Table 2: Quantities of activation at a temperature 293.15 K for [3H]clobenprobit 
at gpH3R. The presented data are based on table 2 given in [14].
ΔG≠
[kJ/mol]
ΔH≠
[kJ/mol]
ΔS≠
[kJ/(mol K)]
ΔCp
≠
[kJ/(mol K)]
association 27 86 0.2 9
dissociation 76 105 0.1 1
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Thermodynamic Discrimination of Antagonists and 
Agonist – A Critical View
Within several studies, a thermodynamic discrimination of 
antagonists and agonists was found [22-24]. But for a distinct 
number of GPCRs, a thermodynamic discrimination of antagonists 
and agonists could not be shown [22-24]. It is very important, that 
such thermodynamic studies are performed very carefully. First, it is 
absolutely necessary to include a large number of ligands with large 
structural variety. In this context, it is worth to look onto the results 
with regard to the histamine H1 receptor [13]. In the corresponding 
study, eight antagonists and sixteen (partial) agonists were included. At 
gpH1R, the antagonists showed an enthalpy of binding in the range from 
1.0 kJ/mol up to 98.8 kJ/mol. However, the antagonist can be divided 
into two groups: Mepyramine, diphenhydramine, amitriptyline and 
chlorpromazine (first group) and fexofenadine, terfenadine, mianserin 
and clozapine (second group). For the first antagonistic group, the 
enthalpy of binding was found in the range from 1.0 kJ/mol up to 44.6 
kJ/mol, whereas for the second antagonistic group, the enthalpy of 
binding was found in the range from 65.3 kJ/mol up to 98.8 kJ/mol. The 
antagonists of each of the mentioned groups have one characteristic: In 
the first group, the amine moiety is a secondary amine, whereas in the 
second group, the amine moiety is tertiary. For the (partial) agonists, 
the enthalpy of binding was found in a range from -24.1 kJ/mol up to 
41.8 kJ/mol. The amine moieties in all (partial) agonists of the study are 
secondary. Now, if one includes only antagonists of the first group and 
the (partial) agonists into the study, no thermodynamic discrimination 
would be found. In the contrary case, where only antagonists of the 
second group and the (partial) agonists would be included into the 
study, thermodynamic discrimination would be identified. However, 
the concept of ligand structure, like secondary or tertiary amine 
moieties, as just explained for the H1R, does not work in general. In this 
context, the rat 5-HT1AR has to be mentioned [10]. Within this study, 
the ligands can be divided in antagonists and agonists with secondary 
and tertiary amines in each group: antagonists with a secondary amine 
moiety: S(-)-propranolol, S(-)-pindolol and alprenolol; antagonists 
with a tertiary amine moiety: NAN-190, mianserin, cyproheptadine 
and ritanserin; agonists with a secondary amine moiety: 8-OH-DPAT, 
serotonin, mexamine, DP-5-CT; agonists with a tertiary amine moiety: 
TFMPP, 2-MPP, m-CPP and CGS-12066B. The enthalpic (entropic) 
terms for antagonists with a secondary amine in the range from 22 kJ/
mol to 48 kJ/mol (-88.8 kJ/mol to -61.4 kJ/mol), for agonists with a 
secondary amine are in the range from -65 kJ/mol to 58 kJ/mol (-109.1 
kJ/mol to 20.0 kJ/mol), for antagonists with a tertiary amine in the 
range from 15 kJ/mol to 80 kJ/mol (-109.1 kJ/mol to -46.5 kJ/mol) and 
for agonists with a tertiary amine in the range from 28 kJ/mol to 46 kJ/
mol (-84.4 kJ/mol to -68.6 kJ/mol). Firstly, these data suggest that there 
is no thermodynamic discrimination between agonists and antagonists 
at rat 5-HT1AR. Secondly, the “discrimination” between antagonists 
with a secondary and tertiary amine moiety, as found at H1R, is not 
valid for rat 5-HT1AR. It is remarkable, that the endogeneous ligand 
serotonin as well as mexapine – mexapine exhibits a high structural 
similarity to serotonin – differ significantly in their thermodynamic 
properties, compared to the other analyzed ligands at rat 5-HT1AR. 
Furthermore, only for mexapine and the endogenous serotonin the 
enthalpy of binding is negative. Interestingly, the enthalpy of binding 
of the endogeneous histamine to hH1R or gpH1R is significantly 
negative (hH1R: -37.6 kJ/mol, gpH1R: -24.1 kJ/mol), compared to other 
ligands. Thus, it has to be proved by further experimental studies, if 
the enthalpy of binding of full agonists to biogenic amine receptors is 
negative in general.  
Taken into account all thermodynamic studies addressing GPCRs 
so far, a strict “thermodynamic discrimination” between antagonists 
and agonists could not be observed for all GPCRs. However, for the 
hH1R and gpH1R, a correlation of the enthalpic or entropic terms 
for ligand binding with the experimentally determined efficacy is 
presented (Figure 4) [13,28,35]. These data show that there is no clear 
“thermodynamic discrimination” of antagonists and agonists at hH1R 
and gpH1R. However, the following tendency can be observed: With 
increasing efficacy (Emax) in the series antagonist (Emax=0) → partial 
agonist (0<Emax<100) → full agonist (Emax=100), the enthalpic term 
decreases, whereas the entropic term increases (Figure 4). These findings 
may indicate that the term “thermodynamic discrimination” between 
antagonists and agonists should be extended to “thermodynamic 
discrimination” between antagonists, partial agonists and full 
agonists. Within the thermodynamic studies addressing GPCRs, 
available in literature so far, partial agonists and full agonists were 
not discriminated. Moreover, it has to be taken into account that the 
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Figure 4: Correlation of the Enthalpic and Entropic Term of Ligand 
Binding with the Efficacy for hH1R and gpH1R. The original data can be 
found in literature [13,28,35]. The efficacies, represented as Emax are given 
in %. The efficacy of the full agonist histamine is 
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competition binding assays – used so far for determination of enthalpy 
and entropy of ligand binding – and functional assays to determine 
efficacy, differ with regard to assay conditions, like buffer, other 
reagents or even expression system. This may be an explanation for the 
lack of thermodynamic discrimination in some studies. As discussed 
above, the desolvation energy of the ligand for example, will play an 
important role and may mask a thermodynamic discrimination. In 
order to address this fact, the corresponding desolvation energies have 
to be determined experimentally or predicted via molecular modelling 
studies. Furthermore, an exact description of the binding mode of 
ligands in the binding pocket, including internal water and ions is 
necessary. Taking into account the possibility of a kinetic control of 
the binding process of the ligand to the receptor, and conformational 
change of the receptor, in case of an agonist, the reaction path for 
association and dissociation including the corresponding transition 
states, has to be modelled in a realistic manner. However, it will be 
worthwhile, to perform much more comprehensive studies in the 
experimental and modelling field, in order to investigate, if the concept 
of “thermodynamic and kinetic discrimination of antagonists, partial 
agonists and full agonists” is valid.
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